Fig. 4From: A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraineFrequency (%) of occurrence of nausea, vomiting, photophobia, phonophobia, and osmophobia 2, 4, 24, and 48 h after administration of frovatriptan (open bars) or rizatriptan (striped bars) in the 125 patients of the intention-to-treat populationBack to article page